BRIEF published on 07/24/2024 at 12:35, 1 year 8 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 1 year 8 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 1 year 11 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
PRESS RELEASE published on 04/19/2024 at 18:10, 1 year 11 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 1 year 11 months ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
PRESS RELEASE published on 03/27/2024 at 13:00, 1 year 11 months ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 03/26/2026 at 13:00, 2 hours 21 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 2 hours 21 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 2 hours 22 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 12:45, 2 hours 36 minutes ago Quartz Mountain Reports Strong Warrant Exercise Participation and Provides Exploration Update at Maestro Project, Central British Columbia
Published on 03/26/2026 at 15:05, 15 minutes ago JOY GROUP Announces 2025 Financial Results, Revenue Surpasses US$620M
Published on 03/26/2026 at 15:01, 19 minutes ago EQS-Adhoc: CENIT AG decides to switch from the Regulated Market (Prime Standard) to the Scale Segment of the Frankfurt Stock Exchange
Published on 03/26/2026 at 15:00, 21 minutes ago OLB’s financial performance remains at a consistently high level
Published on 03/26/2026 at 14:35, 45 minutes ago Guidepoint Library Surpasses 100,000 Transcripts, Scaling Real-Time Access to Expert Knowledge
Published on 03/26/2026 at 14:30, 51 minutes ago Delticom publishes Annual Report 2025: Revenues slightly higher than last year, dividend proposal of € 0.12 per share
Published on 03/26/2026 at 07:30, 7 hours 51 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 20 hours 50 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 21 hours 36 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
